This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Xeolas Pharmaceuticals Ltd.. Active years: 2023-2025.
Company Filing History:
Years Active: 2023-2025
Title: Dennis Mark McDaid: Innovator in Pediatric Pharmaceutical Formulations
Introduction
Dennis Mark McDaid is a notable inventor based in Dublin, Ireland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of pediatric formulations. With a total of 2 patents, McDaid's work focuses on improving the delivery of proton pump inhibitors for children.
Latest Patents
McDaid's latest patents include innovative formulations for pediatric suspension systems. These formulations are designed to be storage-stable and include a therapeutically effective amount of a proton pump inhibitor (PPI), such as omeprazole. The formulations are constituted with water prior to administration, ensuring that they are both effective and safe for pediatric use. Additionally, the oral pharmaceutical suspensions comprise water, a PPI or its pharmaceutically acceptable salt, and one or more buffering agents to enhance stability and efficacy.
Career Highlights
Dennis Mark McDaid is currently associated with Xeolas Pharmaceuticals Ltd., where he continues to advance his research in pediatric pharmaceutical formulations. His work is crucial in addressing the specific needs of young patients who require effective medication in a form that is easy to administer.
Collaborations
Throughout his career, McDaid has collaborated with esteemed colleagues such as Maurice Joseph Anthony Clancy and Damien Patrick Flynn. These collaborations have further enriched his research and development efforts in the pharmaceutical industry.
Conclusion
Dennis Mark McDaid stands out as an influential inventor in the realm of pediatric pharmaceuticals. His innovative approaches to formulation development are paving the way for safer and more effective treatments for children.